305 related articles for article (PubMed ID: 32462838)
1. [Metastatic hormone-sensitive prostate cancer: more than just androgen-deprivation therapy].
Mechahougui H; Achard V; Friedlaender A
Rev Med Suisse; 2020 May; 16(695):1098-1101. PubMed ID: 32462838
[TBL] [Abstract][Full Text] [Related]
2. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.
Brungs D; Chen J; Masson P; Epstein RJ
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):105-11. PubMed ID: 24686773
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
5. Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Ghamande SS; Klaassen Z; Wallis CJD
Eur Urol; 2023 Sep; 84(3):350-351. PubMed ID: 37183160
[No Abstract] [Full Text] [Related]
6. Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.
Pinto Á
Cancer Biol Ther; 2014 Feb; 15(2):149-55. PubMed ID: 24100689
[TBL] [Abstract][Full Text] [Related]
7. The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer.
Swami U; Hong A; El-Chaar NN; Ramaswamy K; Diessner BJ; Blauer-Peterson CJ; Sandin R; Nimke D; Agarwal N
J Urol; 2023 Jun; 209(6):1120-1131. PubMed ID: 36789668
[TBL] [Abstract][Full Text] [Related]
8. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
9. Sex Hormones and Prostate Cancer.
Auchus RJ; Sharifi N
Annu Rev Med; 2020 Jan; 71():33-45. PubMed ID: 31613683
[TBL] [Abstract][Full Text] [Related]
10. To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?
Caffo O; Maines F; Kinspergher S; Veccia A; Messina C
Expert Rev Anticancer Ther; 2021 Apr; 21(4):389-400. PubMed ID: 33245666
[No Abstract] [Full Text] [Related]
11. The role of adrenal derived androgens in castration resistant prostate cancer.
Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH
J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619
[TBL] [Abstract][Full Text] [Related]
12. Progress in the treatment of advanced prostate cancer.
Sternberg CN; Petrylak DP; Madan RA; Parker C
Am Soc Clin Oncol Educ Book; 2014; ():117-31. PubMed ID: 24857068
[TBL] [Abstract][Full Text] [Related]
13. Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer.
Alva A; Hussain M
Drugs; 2013 Sep; 73(14):1517-24. PubMed ID: 23959841
[TBL] [Abstract][Full Text] [Related]
14. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
15. Recent trends in the management of advanced prostate cancer.
Ritch C; Cookson M
F1000Res; 2018; 7():. PubMed ID: 30345007
[TBL] [Abstract][Full Text] [Related]
16. Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
Hoeh B; Chun FKH; Mandel P
Chin Clin Oncol; 2024 Feb; 13(1):14. PubMed ID: 37817509
[No Abstract] [Full Text] [Related]
17. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
Pant MK; Abughaban A; Aragon-Ching JB
Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
[TBL] [Abstract][Full Text] [Related]
18. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
Shiota M; Eto M
Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
[TBL] [Abstract][Full Text] [Related]
19. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
Liu JJ; Zhang J
Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
[TBL] [Abstract][Full Text] [Related]
20. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
